Therefore, although not a common mutation found in prostate cancer, its role in CRC could be highly significant especially as it is recognised that β-catenin has the ability to modulate the effects of AR by binding to the NTD, mutations in this region could therefore interfere with this process [23]. This evidence concerns the gene AR and prostate cancer.